Wong J, Rothmond DA, Webster MJ, Weickert CS (2013)
Pattarabanjird, T., Li, C
Immunogenicity: No Antibody Formation A critical safety consideration for any peptide therapy is immunogenicity, the potential to trigger immune system responses that could lead to allergic reactions, reduced efficacy through antibody neutralization, or autoimmune complications
Dan jirrikostitwixxi n-netwerk tal-fibra tal-kollaen, u jtejjeb strutturalment il-laxkezza tal-ilda u t-tikmix
Most relevant peptides: Thymosin alpha-1 for immune regulation and autoantibody reduction KPV for reducing the inflammatory environment that drives thyroid tissue destruction While direct research on peptides for Hashimoto's is limited compared to lupus or MS, the mechanisms are consistent